H.C. Wainwright analyst Ed Arce downgraded Pliant Therapeutics (NASDAQ: PLRX) from Buy to Neutral.The analyst comments "Our Take. This could ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE